Abiraterone

Research summary

The scientific evidence for abiraterone acetate is extensive and centers on its use in men with metastatic castration‑resistant and castration‑sensitive prostate cancer. Multiple phase I, II, III, and post‑marketing studies have shown that oral abiraterone, given at 1000 mg daily with concurrent low‑dose corticosteroids, improves overall survival, radiographic progression‑free survival, and failure‑free survival when added to standard androgen‑deprivation therapy in this patient population. These trials collectively demonstrate robust antitumor activity and clinically meaningful benefits in disease control and quality‑of‑life measures. Data in healthy humans are limited to pharmacokinetic and bioequivalence studies in adult male volunteers, which confirm predictable absorption, metabolism to active abiraterone, and acceptable short‑term tolerability at single doses. These studies do not evaluate benefits in healthy subjects, but they document safety signals related to mineralocorticoid excess and the need for caution with this drug outside oncology indications. The overall research consensus is that abiraterone acetate is a potent androgen‑synthesis inhibitor appropriate only for carefully selected cancer patients under medical supervision, and it is not appropriate as a health supplement for otherwise healthy individuals.